Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback